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I t  is significant that this meeting was sponsored jointly by two divisions of 
The New York Academy of Sciences-Biology and Psychology. This is a 
unique situation and is indicative of the solvent power of these new drugs in 
bringing together the body and the mind. 
In his introduction, Beckman urged that we pay attention to the etiotropic 
action, as he well called it, in contradistinction to the action of agents on 
symptoms. It has also been said that tranquilizers (or ataractic drugs, which- 
ever term will eventually be accepted) make it possible for us to change dis- 
turbed mental patients into undisturbed mental patients. Actually, after 
much discussion we are not even certain whether meprobamate should be 
regarded as a drug of special interest in relation to mental patients or in a 
quite different light. This brings me to the first of the four topics I should 
like to consider: (1) classification, (2) the mechanism of drug action, (3) the 
problems of testing, and (4) the control of the tension level. 
Classi$cation 
Classification has been much discussed within these pages and is ac- 
tually very important in one’s orientation; it is not a matter of purely 
academic interest. As was pointed out by Smith, patients given a drug that 
has become associated with the treatment of mental disease accept i t  unhap- 
pily, even though they are being treated for some totally unrelated illness. 
Also, the intellectual context of the agent matters a good deal to the physician. 
If meprobamate is like aspirin, it  can be compared with a certain group of 
drugs; if it is like chlorpromazine, it is another matter, and it should be com- 
pared with a different group of drugs; if it is like mephenesin or zoxazolamine, 
the situation again is quite different. Greenberg has compared meprobamate 
in the alcoholic-ward units with morphine and with the barbiturates. Smith 
has compared it with other muscle relaxants, as has Schlesinger. Reserpine 
has been compared with one group of agents by one investigator concerned 
with blood pressure and with another group by another investigator concerned 
with mental disease. The classification makes a great difference in what one 
is likely to do or to see, and in the kind of answer obtained. 
I remind you of the two priests, addicted to cigars, who were very unhappy 
over having been prohibited to smoke while participating in the long hours of 
prayer demanded of them. The two men decided finally that it would do no 
harm for each to write his bishop and ask for a relaxation of this proscription. 
One received the answer “no”; the other, the answer “yes.” The first had 
asked, “IS it permissible to smoke while praying?”; the second, “Is it permis- 
sible to pray while smoking?” 
I do not know what eventual decision will be made as regards the use of 
these particular drugs, but it will surely be of importance. I suspect that if 
a given drug finally turns out to be particularly useful in the treatment of 
psychoses and, therefore, receives the label “tranquilizer,” it may help one 
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million individuals, at  most. If the drug turns out to be more valuable in 
the treatment of neuroses and is given the label “sedative,” it may prove useful 
in six million cases or more. If it turns out that the drug is such a minor 
agent that it will help only to put people to sleep and is labeled “hypnotic,” 
then it will be used by perhaps twenty million or more people in the United 
States alone. 
Regardless of the practical importance of classification, however, it will do 
no good to force the issue prematurely. The right terms, in fact the mere ex- 
istence of terms, must follow the initial development of language, and then of 
science. I suggest that the words we now use in and out of our professional 
activities have come into being because, first, someone has noticed a phenome- 
non in nature; second, he has become sufficiently interested in i t  to identify it 
as distinguished from other phenomena and to describe it thus publicly; and, 
third, he and other persons now interested have communicated to one another 
their discoveries concerning it with progressively increasing descriptive power. 
In order to communicate effectively a greater perceptual awareness and dis- 
crimination, more and more differentiating words are needed. As is well 
known, the Eskimos have eighty words describing different states of solid 
water, while we have only six or eight. Snow and ice have more importance 
in the Arctic than they have in warmer regions. 
So far I have considered the development of language for the discriminative 
identification of subclasses as one step, but this by itself does not lead to a 
scientific understanding of the situation. The rudiments of understanding 
appear when the next step is taken, when some attempt is made to classify or 
to analyze these different subentities-to put them, a t  least, into some kind 
of taxonomic scheme, hopefully, into one that fosters further understanding. 
As an example of the difference between the two steps, advertisers have taught 
us a great array of names for different colors. Names are chosen, presumably 
by practical application of the science of psychology, that will have the greatest 
possible appeal to women in order to induce the purchase of particular objects. 
When the wave lengths of any particular color have been established, however, 
the descriptive term becomes meaningless; as soon as the notion of a spectrum 
and ordered wave lengths comes into being, the whole collection of terms for 
color can be replaced by a precise and significant spectral notation. Obviously, 
therefore, it becomes of the greatest importance to analyze the mechanism of 
action of these drugs rather than simply to describe their over-all effects. 
The Mechanism of Drug Action 
I confess to having been astounded a t  the statement of one clinical partici- 
pant that the tension that prevents sleep is abolished by the action of mepro- 
bamate on the hypothalamus. I was surprised that anyone had found this 
out so precisely and was able to make a positive statement about it. I was 
even a little surprised a t  the more cautious clinician who, in effect, apologized 
for not being able to answer a question regarding the site of action of mepro- 
bamate on the nervous system. 
Leo Alexander has made a point worth considering in offering a complex 
method of distinguishing between anxiety located in the hypothajamus and 
depression located mainly in the cortex. With this attempt I found myself 
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in sympathy, as I have made similar efforts in the past and, especially, as Alex- 
ander has claimed that his method permits realistic testing. I should even 
like to suggest the kind of test that would serve in this case. At least one 
critical action of the mechanism that he described as a t  work was a negative 
feedback from the upper to the lower level. Too much anxiety in the lower 
level fires the upper level, which then inhibits the lower level, so that anxiety 
tends to be relieved by excess depression. This would mean-if one takes the 
dangerous liberty of equating mental phenomena with neurophysiological 
mechanisms-that, where this happens psychologically, appropriate parts of 
the hypothalamus are being inhibited. In turn, this means that the threshold 
to a stimulus should be raised there. An indwelling electrode in an appropriate 
hypothalamic region should then reveal a rise in electrical threshold at the time 
of depression or anxiety. I say this, of course, in partial jest, but if one does 
pretend to test hypotheses of this sort objectively, this is how it must be done 
and, a t  least in using animals, it  is perfectly possible to do so. I n  fact, my 
associates and I did just this in studying the action of epinephrine on the central 
nervous system. Probe electrodes in different regions determined threshold 
changes-of motor cortex, knee jerk, and hypothalamus-after the adminis- 
tration of various doses of epinephrine. 
Nevertheless, this positive statement serves to point out the present negative 
situation. Even such a serious attempt to find a method that will formalize 
drug action and lend itself to objective testing on humans is, today, more or 
less a dream. However desirable such an attempt may be and however fruit- 
ful it  may ultimately become in accounting for the action of these various 
agents in terms of their precise mechanisms of influencing the nervous system, 
a t  present it would be premature to make any dogmatic statements regarding 
mechanism. I doubt if anybody knows enough about any drug to have more 
than a private opinion as to the directions and significance of his laboratory 
explorations. 
Let me exemplify with one “fact,” accepted for many years and referred to 
many times throughout this publication, that seems to me an illegitimate ex- 
trapolation from the actual experimental data. I refer to the statement that 
mephenesin acts by inhibiting interneurons. As far as I know, mephenesin 
depresses the polysynaptic more than the monosynpatic reflexes. It is possible 
that it does so by interfering with interneurons; but it is a gross extrapolation 
of existing knowledge to accept this as a fact in the absence of other evidence. 
Almost any nonspecific deleterious influence on the spinal cord-low oxygen, 
low temperature, low sugar, wearing out of the preparation-is likely also to 
depress the multisynaptic more than the monosynaptic reflexes, and would do 
so even if all cells and synapses were affected alike. The reflex that requires 
the most facilitation a t  some junction would be the first to fail; the more synap- 
ses, the more likelihood of this effect. There may be no quantitative difference 
a t  all between cells. Many types of neurons do exist in the cord as well as in 
the brain, and specific drug actions are quite reasonable. I doubt, however, 
that such an effect has been demonstrated here. 
I choose this point, not to denigrate our presumed knowledge, but to empha- 
size, in a case where even the laboratory scientist has dared to make positive 
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statements, how careful one must be in drawing such conclusions. In  fact, 
it is precarious even to state that a drug is a stimulant or depressant to the 
nervous system when the observation is based on a change in total behavior 
and sometimes even when it is supported by particular observation of the 
activity-for example, the electrical responses-of one center or another. Re- 
call the simple balance, with a pan on each end and the pointer centered a t  
equality. An increased weight on one side, adding excitation, or a decreased 
weight on the other, removing inhibition, would tip the pointer to overactivity 
or “excitation,” and the reverse to underactivity or “depression” of total be- 
havior. A drug that stimulates all neurons can add weights on both sides, can 
tip the scales to convulsions or to coma, depending on whether the action is 
greater on the excitatory or the inhibitory systems. A drug that is a general 
depressant can do the same. Without real knowledge of the actual situation, 
any conclusion as to mechanism is dangerous. 
I t  is even useful to raise the question whether a given drug a t  different doses 
always has the same action in varying degree, or can reverse its action, or can 
act in different ways in different places. At the most general level there is a 
quantitative gradient along the neuraxis; the upper end is most active meta- 
bolically and physiologically-as the pacemaker of the heart is-and the more 
active regions are knocked out by progressive depression more easily than are 
the less active areas. Thus anesthetics knock out the “higher” centers before 
the “vital” centers of the brainstem and so permit anesthesia without death. 
Hypoglycemia, or low oxygen, also gives a progressive chopping off along the 
quantitative gradient. On this basis one might think of some drugs as pro- 
ducing effects a t  the upper end of the nervous system more easily than a t  the 
lower end. Relatively speaking, such drugs presumably would modulate the 
finer nuances of behavior and subjective experience more than they would de- 
press or exaggerate the reflex behavior of the lower part of the nervaus system. 
However, it is equally possible-in fact, it  is one of the great hopes of psycho- 
pharmacology-that specific chemical agents may differentially activate, de- 
press, or modify the behavior of particular functional systems in the nervous 
system. If this proves to be the case, such drugs will make fine tools-in con- 
trast to such gross tools of regional lesions or stimulation-for working out the 
concomitant variations in personality, in symptom complexes, and in clinical 
entities, and for relating them, ultimately, to particular detailed functional 
subsystems of the nervous system. 
The paper by Baird et al., showing a differential action of the drugs concerned 
here on various parts of the basal nuclei, is relevant to this point. Quite aside 
from action a t  a general level, and without specificaIIy affecting particular 
parts of the nervous system, a drug may have profound effects simply by alter- 
ing time relations. This may be the main moral of Hess’s paper on imprinting, 
in which the exciting observation was made that, with drugs, one could delay 
imprinting-the nervous system of treated ducklings did not imprint a t  the 
age of 13 hours, as it normally does, even though the ducklings were wobbling 
about, but a t  20 hours or a t  some subsequent time. This implies a change in 
tempo of the maturation process itself. Further, it was suggested that this 
particular imprinting was merely one stage in the development of the nervous 
system, that there are specific times for imprinting such characteristics as 
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docility, mating behavior, decent performance in the herd or, more broadly, 
socialization, and the like. I wonder if there exist specific kinds of suscepti- 
bilities of the nervous system a t  different times or if the cumulative behavioral 
capacities allow the fixation of more and more complex patterns. 
The whole of biological and psychological 
development is a series of appropriate reactions to appropriate experiences in 
the right sequence. Drugs that would simply slow up certain activities or 
throw them out of phase with others could have tremendous impact on the 
behavior, even though no particular cell were stimulated or depressed and no 
particular enzyme were rendered ineffectual or activated. It could all be a 
disturbance of the patterns rather than the units. This deserves emphasis. 
If, from a paragraph or even a sentence of type, we drop out all the e’s or all 
the t’s, we should probabIy still be able to read the text without difficulty. 
Dropping out such a series of letters would be equivalent to knocking out a 
major enzyme system. If, however, we leave all the letters in any passage, 
but mix them up, there will be practically no chance of our making any sense 
of it. 
Returning to the problem of gross levels, it  has been said that a battery of 
careful psychological tests given to patients of various kinds has indicated that 
dexedrine had the same effect as that of a prefrontal leukotomy ; chlorproma- 
zine, as that of a cingulate gyrus lesion. I do not know whether these findings 
will hold up, but this seems to be a useful kind of approach. This is the way, 
more precisely, to establish a link between the anatomical and physiological 
on the one side, and the behavioral on the other. At the Mental Health Re- 
search Institute last year we tried a similar experiment. Individuals were made 
hyperthyroid and were returned to normal in the hope that responses to a 
certain group of psychological tests would change, but that others measuring 
different parameters of the psyche would not do so. Unfortunately, the results 
did not show a clear separation. 
I should like to consider specifically the question of muscle tone and steadi- 
ness, and tremor and anxiety-they do link up physiologically-because they 
have received so much attention. I remind you that the degree of alertness 
of an individual, whether awake or asleep, is determined by, among other fac- 
tors, the degree of muscle tension, and so by the feedback from the muscle 
proprioceptors and the flow of impulses up to the higher centers. Various 
agents cause both increased tension and tremor and increased anxiety. One 
of the best examples is epinephrine itself, which is liberated in association with 
anxiety and thus can serve as a positive feedback mechanism. Dickel reported, 
however, that his patients, given meprobamate, showed a substantial decrease 
in the action potentials of their muscies, but no change in the psychological 
concomitant of anxiety and worry. Harriet Gillette attempted to analyze 
the drug action neurophysiologically and to distinguish between pyramidal 
and extrapyramidal defects-certainly a step in the right direction. She also 
made inferences that conformed with those of Schlesinger, but with a somewhat 
less positive final conclusion as to their present usefulness. 
I conclude by saying that, although I completely favor experimental analysis 
of the action of these drugs and regard this as ultimately the necessary and 
sound way of ascertaining their potentialities, and so of improving the drugs 
Let me generalize still further. 
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and their actions, I think we must be very careful not to reach premature and 
uncertain conclusions. For the time being, those who hold to a statement of 
what they actually observe-the flaccid feel of a muscle, the occurrence of 
certain electrical changes, the particular performance of a patient-are likely 
to contribute most. 
I am especially directed toward this conclusion by the exchange between 
Berger and Pfeiffer, the two pharmacologists who have actually tested mepro- 
bamate in some detail on animals. These investigators could not even agree 
on the actual experimental findings in a number of instances. Obviously a 
third element will be needed to resolve this. Since one of the disagreements 
involved the question as to whether patients under meprobamate slept quietly 
or squirmed around in bed like eels, I could not help but remember the story 
of the electrophysiologist who led an expedition up the Nile and brought back 
an electric eel to study. The eel gave shocks nicely for a while, but then grew 
despondent, slumped in the aquarium, and would not perform. The experi- 
menter had learned something of the eel language and when he asked why, the 
eel replied, “It is the mating season now, and I am lonesome. I should like 
another eel.” The experimenter, being human as well as scientific, arranged 
another expedition, and soon a female eel was put in the tank. After a moment 
of twining ecstasy, however, the two went to opposite sides and the first eel 
was more despondent than ever. When asked again, “What is wrong? ” he 
said, “Alas, I am A.C. and she is D.C.!” 
The Problems of Testing 
I shall deal briefly with the problems of testing, since they have been dis- 
cussed a t  some length in the recent symposium “The Evaluation of Pharma- 
cotherapy in Mental Illness.” Questions raised in this publication that were 
extensively discussed in that conference include : behavioral toxicity, which 
does need much emphasis in dealing with behavior-affecting drugs, agents that 
yield the particular effect desired only at  some price, in performance if not in 
liver function; the problem of transferring to man the results of experiments 
made on animals; and the influence of a group of patients on the effects of a 
drug-raised here by Sabshin, Greenberg, and others. 
I was impressed by the report of the different relative effects of the drugs on 
different nursing units. Partly, this seemed related to the severity of the 
disease, but partly it seemed related also to the unique personalities or indi- 
vidualities of the units. When Greenberg pointed out that, in the alcoholic 
institute, even placebos gave almost 40 per cent improvement (meprobamate 
gave twice as much, and the difference was significant statistically) I wondered 
whether the subjects had been located in the same units. The progressive 
quieting of the unit, due to the actual soothing of disturbed and disturbing 
patients by the drug (and obviously easily measurable by a global index, such 
as the decibels of general noise level of a ward), might have decreased the ten- 
sions of those not getting meprobamate, so what was regarded in this case as a 
placebo effect may have been, so to speak, a reverberation of quiet from the 
true action of the drug. Similarly, one’s own level of conversation fluctuates, 
depending upon the noise in the room. The installation of soundproofing 
in a ceiling by itself can lower stress. 
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At the experimental level of drug testing, the particular problem is that of 
determining the proper factor for which to look. There is no sense in trying 
an agent on an animal or on a human who does not manifest the phenomenon 
the agent is expected to influence. I t  would have been difficult to find the 
antibiotic activity of penicillin by giving it only to healthy animals and men. 
Thus, either the kind of symptom to be influenced must be clearly present or 
it must be produced. Producing symptoms (convulsions, hallucinations, anx- 
iety) with one drug and then searching for the drugs that will counteract these 
symptoms is similar to the case of the eminent neurologist who was approached 
by a patient for treatment of her indigestion. He assured her that he did not 
treat indigestion, but she insisted that he had been very highly recommended 
and she wanted him as her doctor. After a long argument he finally said, “I 
can give you a medicine that produces fits, and I am expert a t  curing fits.” 
Next comes the problem of the validation of findings and the relation to dose. 
On certain phenomena drug action was obtained only a t  very high doses. This 
seemed the main import of Hunt’s experiments with meprobamate, and equally 
of Pfeiffer’s. On the one hand, laboratory studies indicate that meprobamate 
is quite inert; on the other hand, a great number of takers seem to experience 
some benefit, and clinical reports included in these pages-many seemingly 
well controlled and convincing enough as reported-indicate a definite action. 
From this one must conclude either that the experimenters have not yet found 
the right thing to test-which would not be surprising, since we are dealing 
with agents active on the nuances of complex human behavior for which it is 
difficult to find electrical or chemical indicators, either in the laboratory or in 
the patient-or else that the clinical impressions are wrong and that some day 
these will follow phlebotomy, laudable pus, and other major medical mistakes 
into the discard. I doubt that the latter is the case, especially because of the 
genuine awareness of the problem of controls that exists today among the 
better clinicians and laboratory workers handling these problems. 
We have heard much about the double blind and the placebo. The double 
blind has been described as an experiment in which everybody but the doctor 
knows what is being given; a report of a double-blind experiment on promazine 
and chlorpromazine, which act very similarly, supports this definition. The 
statement was made that the patients knew by the end of the first day whether 
they were getting A or B ;  that the ward attendants and the nurses knew which 
were which by the end of the second day. Greenberg has stated that, as re- 
gards meprobamate and placebo, the case was reversed; doctors, either more 
intelligent or having more contact with the patients, became aware of the 
results before the ward attendants did (I do not know whether or not the pa- 
tients ever did). 
A placebo, of course, means something that placates or pacifies or tranquilizes 
-perhaps we should really use the word “tranquilizer” for the placebos and 
not for the drugs being tested-but from evidence presented in these pages, 
they seem to have had a dynamic and exciting influence rather than a pacifying 
one. In general there has been a tendency to regard placebos in an “all-or- 
none” fashion and to take hostile positions concerning them. Some statements 
have been made that I should not have made myself. For example, it is well 
to compare the unknown agent, not with a completely inactive substance, but 
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with another agent possessing comparable activity. Here the observer is, so 
to speak, titrating a smaller difference, and this can be magnified more. Again, 
the need for using a placebo of any kind depends on the particular situation 
involved. With a sufficiently objective measure of something not immediately 
responsive to suggestion (either in the patient or the doctor), it  is patently 
unnecessary to use a placebo. This resembles the situation in the chemical 
laboratory, where the agent is added to one test tube and not to the other; 
it is not necessary to add a like amount of water to a third tube just to fool it. 
Consider the case, described by Schlesinger, of certain patients who, after 
showing negative results for years on being tested with one after another agent, 
suddenly responded positively to a new agent. One could be pretty sure, in 
this case, without using a placebo and barring other significant change, that 
this agent was active. 
The clinical “hunch” must always be the first step, and its earmark is a 
phrase containing, “I feel,” “I believe,” “I feel that my patients are helped,” 
or “I believe the drug is doing good.” This is the sine qua non to further de- 
velopments. I t  is what has been called the retail point of view. One is con- 
cerned with the individual, accumulates a number of individual cases, and 
draws conclusions from a consideration of these cases. Without such a con- 
viction one would never know what kind of exact tests to make or what things 
to look for when the drugs are administered. So there is no conflict between 
this and the other type of approach, that of the experimentalist and that of 
the statistician or actuary-t he wholesale point of view. The experiments 
and statistics of the objective scientist are just as necessary in verifying a 
hunch as clinical art  is necessary in its inception. I assure you that getting 
the right hunch is by far the more creative part of the job; but testing the 
hunch is by far the most important part and the one requiring the greatest 
expenditure of time and care. 
My own impression from the papers, particularly on the clinical side, is that 
meprobamate does act strongly on what might be called symptomatically (I 
here may violate some caoeats I made earlier) the tension level. This level 
helps control stress or decrease tension, whether in terms of lessened downward 
discharges to muscles and easing of spasticity, of lessened discharges upward 
to the cortex (or the psyche or superego) with an easing of hostility, directed 
outward or inward, of anxiety, or of some other factor. 
Control of Tension Level 
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Enthusiasm over the action of meprobamate in making patients co-operative 
has been expressed in a number of papers, Senile, alcoholic, and other sad 
relics, who would not accept help from willing and friendly ward personnel, 
abandoned their stubborn resistance. This is obviously a good and helpful 
effect and indicates a valid use for any drug that can produce it. One could, 
however, as implied by Huxley, use another word for “co-operative.” One 
could say the drug makes people docile, renders them susceptible to outer in- 
fluences, including the “big brother” variety and brain washing. As Dickel 
asks, what are the criteria that one should consider in judging effective thera- 
peutic results of a drug? They include not only the feelings of the patient, 
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but also his performance in the community, whether or not he can hold a job 
and interact with his fellows. 
Two basic antinomies arise here: the conflict within the individual, between 
the desire for nirvana and the desire for experience; and the conflict between 
the individual and the group, for the peace of the individual and the progress 
of the society or species. As far as the group is concerned-and I should use 
here the term “epiorganism”-it is certainly true that, throughout evolution, 
selection of individuals to be parents for the next generation has had nothing 
to do with the welfare of those individuals. In  most cases the selection has 
been an entirely painless one in terms of slight advantages in adaptive mech- 
anisms but, in many situations, the individuals are ruthlessly sacrificed for the 
good of the group. 
This is really the theme of the legend of Prometheus, who stole fire from 
heaven. He brought progress for mankind but, as an individual, he suffered 
the tortures of being torn by ravens. The conflict between the individual and 
the group also underlies the ethical problem in human experimentation that 
has been aired here. Is it ever ethically permissible to withhold from a patient 
that treatment which, a t  the moment, is regarded as the best and most satis- 
factory? If not, how could one test the new, or give placebos to controls, or 
try uncertain remedies? Conversely, under what conditions is it desirable or 
ethically permissible to try on a patient something that may be better than 
the current agent but which may also prove harmful? When does one stop 
using the good in an effort to achieve the better? This is a very basic ethical 
problem and it bothers all who operate in this field, not only morally, but even 
legally. I t  is not easy to answer the question: “What calculated risk is per- 
missible with a given human individual for a potential great gain to mankind 
as a whole?” 
Turning, finally, to conflict within the individual, there are a number of 
interesting points. Consider the new techniques of allowing monkeys with 
indwelling electrodes in the brain to give themselves shocks. If the electrode 
is in a region associated with painful experience, an animal presses the lever 
once, jumps, and never touches it again. If the electrodes are elsewhere, how- 
ever, in the limbic system and its adnexae, the animal is likely to continue 
punching the lever for long periods, and will even undergo some external dis- 
comfort in order to do this. The question arises “What does he get out of 
it?” There has been a tendency, with some justification for certain regions 
of the brain, to think that the shocks arouse the equivalent of sexual feelings; 
if such feelings can be produced centrally, without wearing out the peripheral 
mechanism, continuing elicitation is understandable. I t  may not be as simple 
as this, however; there is some reason to believe that, rather than pleasurable 
experience, the stimuli may give only nirvana. Children with petit mal, who 
can bring on an attack with a flickering light, may spend hours in the sunshine 
waving their fingers before their eyes and having attack after attack. They 
behave in many respects like the monkeys; conversely, the monkey behavior 
is perhaps directed to a negative effect. Are these animals seeking a positive 
.pleasure or a negative absence of experience? Here, a t  least, is a technique 
only beginning to be exploited that may lead to many clear-cut answers to 
such questions. 
I do not presume to resolve this problem; I simply state it. 
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More immediately I remind you that, both in the evolution of the species 
and in the development of the individual, with the increase of the functioning 
cortex there is a progressive emergence of what Kleitman called the wakefulness 
of choice as compared to the wakefulness of necessity. This goes back to 
W. R. Hess’s experiments three decades ago. Animals sleep and are inactive 
except when they must do something about solving the problems of life. This 
is the wakefulness of necessity. With the growth of the cortex there is more 
and more of the additional wakefulness of choice-an extra libido; in Alexan- 
der’s view, the play libido-a desire or the ability to keep going, to be active 
for activity’s sake, ajoie de vivre, a joy of play. 
Huxley has made the point that all natural depressant drugs, tranquilizers 
or whatever one may call them, have been known from antiquity. This is 
certainly true. He did not suggest, however, that all the natural drugs that 
give increased activity, that move one away from a state of peace and nirvana, 
were also discovered in antiquity. Indeed, as far as I know, these are much 
more widely sought and used in every culture than are the depressants. As 
regards primitive or advanced groups, coffee, tea, or mat&, wherever available, 
is the main beverage of the people; the cup that cheers takes precedence over 
the cup that inebriates. I have some apprehension a t  Huxley’s suggestion 
that we try to teach children to control their autonomic nervous systems. It 
took organisms a long time to exclude these actions from voluntary control, so 
that the foofs could not kill themselves off a t  once. By way of answering 
I-Iuxley’s concluding question, I rather suspect that, even though we are now 
tampering with the upper part of our nervous system, we shall survive without 
serious damage. 
There is certainly something like an 6Zan vital effective in all living creatures, 
pointed up in man as a “divine unrest.” Biology would give a positive answer 
to the question that the poets and the humanists have raised and have answered 
in all possible ways and nuances. The biologist stands with Louis Untermeyer 
rather than with Swinburne, and therefore subscribes to the second of 
these verses: 
“From too much love of living, 
From hope and fear set free, 
We thank with brief thanksgiving 
Whatever gods may be 
That no life lives for ever; 
That dead men rise up never; 
That even the weariest river 
Winds somewhere safe to sea.” 
‘‘From compromise and things half-done, 
Keep me, with stern and stubborn pride; 
And when, a t  last, the fight is won, 
God, keep me still unsatisfied.” 
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